Marker Therapeutics Inc
(FRA:GX1)
€
4.96
0.3 (6.44%)
Market Cap: 47.88 Mil
Enterprise Value: 31.25 Mil
PE Ratio: 0
PB Ratio: 4.24
GF Score: 48/100 Marker Therapeutics Inc (FRA:GX1) Transcripts
- Marker Therapeutics Inc to Participate in the Beyond CAR-T: What's Next for Cell Therapy Event TranscriptAug 09, 2023
- Marker Therapeutics Inc to Host Clinical Program Update Call TranscriptFeb 16, 2022
- Marker Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) TranscriptJun 21, 2021
- Q1 2021 Marker Therapeutics Inc Earnings Call TranscriptMay 12, 2021€19.1 (-1.04%)Earnings
- Q3 2020 Marker Therapeutics Inc Earnings Call TranscriptNov 09, 2020€12.7 (+8.55%)Earnings
- Marker Therapeutics Inc MultiTAA-Specific T Cell Therapy in Patients with Pancreatic Adenocarcinoma at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting TranscriptJun 01, 2020
- Q1 2020 Marker Therapeutics Inc Earnings Call TranscriptMay 11, 2020€22.8 (+8.57%)Earnings
- Q3 2019 Marker Therapeutics Inc Earnings Call TranscriptNov 12, 2019€35.64 (-0.03%)Earnings
- Marker Therapeutics Inc Special Call TranscriptJul 22, 2019
- Marker Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference TranscriptMay 16, 2019
- 1